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ABSTRACT
Background: We compared the clinical characteristics, findings, and outcomes of hospitalized patients with coronavirus
disease 2019 (COVID-19) or influenza to detect relevant differences.
Methods: From December 2019 to April 2020, we recruited all eligible hospitalized adults with respiratory infection to a
prospective observational study at a tertiary care hospital in Finland. Influenza and SARS-CoV-2 infections were confirmed
by RT-PCR. Follow-up lasted for 3 months from admission.
Results: We included 61 patients, of whom 28 were COVID-19 and 33 influenza patients with median ages of 53 and 56 years.
Majority of both COVID-19 and influenza patients were men (61% vs. 67%) and had at least one comorbidity (68% vs. 85%).
Pulmonary diseases and current smoking were less common among COVID-19 than influenza patients (5 [18%] vs. 15 [45%],
p¼.03 and 1 [4%] vs. 10 [30%], p¼.008). In chest X-ray at admission, ground-glass opacities (GGOs) and consolidations were
more frequent among COVID-19 than influenza patients (19 [68%] and 7 [21%], p<.001). Severe disease and intensive care unit
(ICU) admission occurred more often among COVID-19 than influenza patients (26 [93%] vs. 19 [58%], p¼.003 and 8 [29%] vs. 2
[6%], p¼.034). COVID-19 patients were hospitalized longer than influenza patients (six days [IQR 4-21] vs. 3 [2–4], p<.001).
Conclusions: Bilateral GGOs and consolidations in chest X-ray may help to differentiate COVID-19 from influenza.
Hospitalized COVID-19 patients had more severe disease, required longer hospitalization and were admitted to ICU more
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Introduction
Coronavirus disease 2019 (COVID-19) pandemic caused
by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is currently causing such dramatic effects
on health, economy and society as a whole that sea-
sonal influenza, disruptive as it is, may seem to pale in
comparison. However, several influenza pandemics have
swept the globe and pandemic preparedness plans now
used for COVID-19 are based on lessons from influenza.
Understanding the differences in their epidemiology and
clinical course is crucial for planning appropriate control
measures for future COVID-19 mitigation.
COVID-19 first emerged in Wuhan, China, in
December 2019 and spread to a worldwide pandemic
by March 2020 [1–4]. By 27 September 2020, over 32.7
million cases and 991,000 deaths had been reported glo-
bally [5]. In comparison, the pandemic A (H1N1) virus
caused an estimated 151,700–575,500 respiratory and
cardiovascular deaths during the first 12 months of the
latest influenza pandemic of 2009–2010 while seasonal
influenza is estimated to be responsible for
291,243–645,832 respiratory deaths annually [6,7].
The clinical presentations of COVID-19 and influenza
vary from mild respiratory tract infection to severe viral
pneumonia leading to acute respiratory distress syn-
drome (ARDS) and death [3,8–12]. In the largest study
on COVID-19 to date, 80.9% of cases were considered
mild, 13.8% severe and 4.7% critical [8]. A proportion of
SARS-Cov-2 infections appear to be asymptomatic yet
contagious [13,14]. Transmission can occur 1–2 days
before symptom onset in both influenza and COVID-19
and recent studies suggest that even earlier transmission
is possible in COVID-19 [15–17]. Fever and cough are
the most common symptoms in both infections while
fatigue, myalgia, headache and dyspnoea may be pre-
sent [3,8–10,12,18,19]. Gastrointestinal (GI) symptoms
occur in almost 20% of COVID-19 and 3–31% of influ-
enza patients [20,21]. Olfactory and taste disorders are
associated with COVID-19 [22].
Well-known high-risk groups of influenza include eld-
erly, pregnant women, under 2-year-old children and
people with pre-existing comorbidities [12,19].
Established risk factors for the development of severe
infection, ARDS and death in COVID-19 include older
age, male sex and comorbidities [8,10,11,18,23–25].
While 80% of deaths occurred among under 65-year-
olds during the 2009 A (H1N1) influenza pandemic, the
mortality caused by COVID-19 has been highest among
80þ-year-olds [6,8]. In case of seasonal influenza, highest
excess respiratory mortality rates occur among people
aged 75 years of older [7].
In Finland, the first cases of COVID-19 appeared in
the Hospital District of Helsinki and Uusimaa in late
February and since 17 March 2020 a nationwide lock-
down was put in place (Figure 1). Our prospective popu-
lation-based influenza study was already recruiting
Figure 1. Weekly COVID-19 and influenza cases in the study (bars) and in the whole Hospital District of Helsinki and Uusimaa (lines)
between December 2019 and April 2020. Influenza and SARS-CoV-2 detections in the Hospital District of Helsinki and Uusimaa (HUS area)
were obtained from the National Infectious Diseases Register (NIDR). Since 17th of March (week 12), nationwide lockdown was in place.
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hospitalized adult patients with severe acute respiratory
infection (SARI), which gave us the opportunity to enrol
COVID-19 patients since the beginning of the outbreak.
We compared the clinical characteristics and outcomes
of hospitalized adult COVID-19 and influenza patients to
provide information for clinical diagnostics and public
health strategies used in COVID-19 mitigation.
Materials and methods
Study design
We conducted a prospective observational study at the
HUS Helsinki University Hospital, Jorvi Hospital, Espoo,
Finland together with the Finnish Institute for Health
and Welfare (THL) as a part of the international DRIVE
collaboration (www.drive-eu.org). The study was primar-
ily focused on estimating influenza vaccine effectiveness
and disease burden but its objectives included collecting
data on other respiratory pathogens for the needs of
national surveillance.
The study was approved by the Local Ethics
Committee of the HUS Helsinki University Hospital.
Appropriate study permits were obtained from the
University Hospital, THL and the municipalities involved.
Informed consent was obtained from the patients or the
next of kin of those critically ill.
Study population
Jorvi Hospital, which is a tertiary care hospital of the
HUS Helsinki University Hospital, provides specialized
care for the 339,000 residents of the cities of Espoo,
Kauniainen and Kirkkonummi. All community-dwelling
adult (18þ-year-old) SARI patients admitted to the hos-
pital were interviewed by a study nurse and recruited to
the study if they fulfilled the eligibility criteria listed in
the study protocol and gave their informed consent
[26]. A SARI patient was defined as a hospitalized person
with at least one systemic symptom (fever or feverish-
ness, malaise, headache or myalgia) or deterioration of
general condition (asthenia or loss of weight or anorexia
or confusion or dizziness) and at least one respiratory
symptom (cough, sore throat, shortness of breath) at
admission or within 48 h after admission. Initially, only
patients with symptom onset within the last seven days
were eligible; however, during the COVID-19 epidemic,
SARI patients were recruited symptom onset notwith-
standing to include all COVID-19 patients. Patients were
followed up for 3 months from admission.
Data collection
Data were obtained from patient interviews and elec-
tronic medical records by the study nurses and physi-
cians. Comorbidities, smoking, influenza vaccinations,
SARI symptoms, triage vitals, routine laboratory test
results and radiological images, intensive care unit (ICU)
admission, invasive mechanical ventilation and outcomes
were collected. Overnight hospitalizations during the
past 12 months were collected and verified from the
Care Register for Health Care (HILMO). The severity of
chronic conditions was assessed using the McCabe score
(1¼non-fatal, 2¼ fatal in 1–4 years and 3¼ fatal within
a year). National Early Warning Score 2 (NEWS2) at
admission was calculated. The severity of infection was
classified as in WHO interim guidance for COVID-19 [27].
In short, the categories were mild disease (uncompli-
cated upper respiratory tract viral infection), pneumonia
(no signs of severe pneumonia nor need for supplemen-
tal oxygen), severe pneumonia (respiratory rate
>30 breaths/min, severe respiratory distress or
SpO2 93% on room air) and ARDS (as defined by the
Berlin Definition). In case of readmission to the hospital
for the same reason within three days of hospital dis-
charge, the hospitalization was reported as one episode.
Routine laboratory test results at admission and high-
est or lowest values during hospitalization and radio-
logical imaging were extracted. Chest X-ray images were
interpreted by a radiologist unaware of the microbio-
logic diagnosis of the patients. Anaemia was defined as
haemoglobin <134 g/L for men and <117 g/L for
women, leukopenia as white blood cells <3.4 109/L
and lymphopenia as blood lymphocytes <1.2 109/L
and thrombocytopenia as platelet count <150 109/L.
Laboratory testing for respiratory pathogens
Respiratory samples taken from nasopharynx, orophar-
ynx or trachea for routine diagnostics were tested at the
Helsinki University Hospital Laboratory (HUSLAB).
Influenza testing was performed using XpertVR Xpress Flu/
RSV assay (Cepheid, Sunnyvale, CA). For the detection of
SARS-CoV-2 RNA, the specimens were subjected to one
the following three methods: (1) the real-time labora-
tory-developed SARS-CoV-2 RT-PCR based on Corman
et al., 2020; (2) Roche Molecular Systems cobasVR SARS-
Cov-2 assay (Branchburg, NJ, USA); (3) the
AmplidiagVR COVID-19 assay (Mobidiag, Helsinki, Finland).
Influenza virus subtypes or lineages were defined at the
THL Expert Unit for Microbiology. If influenza testing
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was not done at HUSLAB on clinical grounds, it was per-
formed at THL with the exception of seven COVID-19
patients, whose samples could not be located. Since 13
March 2020, all patients hospitalized with a suspected or
diagnosed respiratory infection were tested for SARS-
CoV-2 at HUSLAB according to the local testing strategy;
before that, testing was conducted based on individual
consideration e.g. travel history to an epidemic area or
known exposure to COVID-19. However, as a part of this
study, all samples tested for influenza at THL were also
tested for SARS-CoV-2.
Statistical analysis
Categorical (described as proportions) and continuous
(described as medians and interquartile ranges) variables
were compared using Fisher’s exact test and
Mann–Whitney’s U-test, respectively. Statistical analyses
were performed using SPSS version 26.0 (IBM SPSS
StatisticsVR , Armonk, NY) and Stata 16.1 (StataCorp,
College Station, TX). To analyse predisposing factors pre-
dicting the duration of hospitalization, we did a multi-
variable Cox regression analysis for the hazard of
discharge from the hospital. We entered COVID19, age,
sex, BMI and comorbidities (including anaemia, cancer,
cardiovascular disease, diabetes, hypertension, immuno-
suppression, kidney disease, liver cirrhosis, neurological
diseases, pulmonary diseases, rheumatic diseases and
stroke) into the Cox analysis and used backward selec-
tion using Akaike information criterion (AIC) to choose
our final model. The predictors chosen in the final
model were COVID19, age, BMI and diabetes.
Results
Between 2 December 2019 and 30 April 2020, we
recruited altogether 213 eligible SARI patients, of whom
those 61 patients positive for either SARS-CoV-2 (28) or
influenza (33) by RT-PCR were included in this study. All
except two influenza patients were recruited before
week 12, whereas all COVID-19 patients were recruited
from week 12 onwards (Figure 1). Of the influenza
patients, 29 (88%) were positive for influenza A (H1N1)
pdm09, two (6%) were positive for influenza A (H3N2)
and two (6%) for influenza B/Victoria. All influenza
patients were tested for SARS-CoV-2 and 21 (75%) of
COVID-19 patients were tested for influenza and no co-
infections were found. The median ages of COVID-19
and influenza patients were 53 (range 18–81) and 56
(19–87), and the majority were men (17 [61%] vs. 22
[67%]) (Table 1).
At least one comorbidity was present in 19 (68%) of
COVID-19 and 28 (85%) of influenza patients (Table 1).
In COVID-19 patients, the most common comorbidities
were obesity (11, 41%) and hypertension (8, 29%)
whereas in influenza patients hypertension and pulmon-
ary diseases were most prevalent (15, 45%, respectively).
Pulmonary diseases and current smoking were signifi-
cantly less common among COVID-19 than influenza
patients (5 [18%] vs. 15 [45%], p¼.03 and 1 [4%] vs. 10
[30%], p¼.008). Fatal comorbidities (McCabe score 2 or
3) were slightly less prevalent among COVID-19 than
influenza patients (2 [7%] and 7 [21%], p¼.160). None of
the COVID-19 patients had been previously hospitalized
during the last 12 months compared with nine (27%) of
influenza patients (p¼.003). No difference was observed
in the proportion of influenza vaccinated for 2019–2020
season among COVID-19 and influenza patients (12/26
[46%] vs. 16/33 [48%], p¼ 1.00). The vaccination status
of two COVID-19 patients remained unknown. The data
showed no difference in the duration of hospitalization,
need for ICU admission or outcome at 30 days from
admission between influenza vaccinated or unvaccinated
patients among either COVID-19 or influenza patients
(Supplement 1).
At admission, the clinical picture of COVID-19 was
similar to that of influenza with reported fever and
cough being the most common symptoms. Headache
was more common among COVID-19 patients (22/25,
85% vs. 16/31, 52%, p¼.004). COVID-19 patients were
hospitalized on average on day 10 of symptoms com-
pared with day 3 for influenza patients (Table 2).
The laboratory results of COVID-19 and influenza
patients that differed significantly at admission included
leukocyte and platelet counts and alanine aminotransfer-
ase (ALAT) (Table 2). CRP values were similar at admis-
sion but rose significantly higher in COVID-19 patients
during hospitalization. ALAT was higher among COVID-
19 patients than influenza patients both at admission
and during hospitalization. Blood cultures were taken
from 23/28 of COVID-19 and 32/33 of influenza patients
and were negative.
In chest X-rays at admission, ground-glass opacities
(GGOs) and consolidations were observed significantly
more often in the images of COVID-19 than influenza
patients (19 [68%] and 7 [21%], p<.001), whereas linear
opacities were more common among influenza patients
(Table 2). Typically, the GGO and consolidations present
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in the images of COVID-19 patients were bilateral and
peripheral or basal (Figure 2). No findings were observed
in five (18%) of COVID-19 and 12 (36%) of influenza
patients (p¼.154). Three of the five COVID-19 patients
with no radiological findings at admission developed
consolidations in chest X-ray within one week.
Severe disease (severe pneumonia or ARDS) and ICU
admission were significantly more common among
COVID-19 patients than influenza patients (26 [93%] vs.
19 [58%], p¼.003 and 8 [29%] vs. 2 [6%], p¼.034) (Table
3). Notably, all patients admitted to the ICU were men.
The median age of the eight COVID-19 patients admit-
ted to the ICU was 60.5 (range 52–61) while the two
influenza patients were 38 and 62 years old. All eight
COVID-19 patients developed ARDS and were mechanic-
ally ventilated compared with one of the two influenza
patients and their median stay at the ICU was 20 (range
11–41) compared with 9.5 (3–16) days. Two COVID-19
patients were at the ICU twice and both episodes were
included in the total duration of their ICU stay.
As of 5 June 2020, 60 of the 61 patients had been
discharged from Jorvi Hospital and one COVID-19
patient had died. COVID-19 patients were hospitalized
significantly longer than influenza patients (six days [IQR
4–21] vs. three days [2–4], p<.001) (Table 3, Figure 3).
To further examine whether there were other factors
predicting the duration of hospitalization besides
COVID-19, we did a multivariable Cox regression
Table 1. Characteristics of COVID-19 and influenza patients.
COVID-19 Influenza
Characteristics N % N % p Value
Total 28 100 33 100
Age
Median (IQR) (range) 53 (44–61) (18–81) N/A 56 (38–73) (19–87) N/A .465
18–64 23 82 21 64 .154
65 or over 5 18 12 36
Sex
Female 11 39 11 33 .790
Male 17 61 22 67
Comorbidities
Anaemia 1 4 4 12 .363
Cancer 2 7 5 15 .437
Cardiovascular disease 4 14 9 27 .347
Coronary artery disease 3 11 3 9 1.000
Congestive heart failure 0 0 4 12 .118
Other 1 4 3 9 N/A
Diabetes 5 18 9 27 .543
Hypertension 8 29 15 45 .197
Immunosuppression 0 0 4 12 .118
Due to medication 0 0 4 12 .118
Kidney disease 1 4 3 9 .618
Liver cirrhosis 0 0 1 3 1.000
Neurological diseases 0 0 4 12 .118
Obesity (BMI  30) 11/27 41 12 36 .793
BMI  35 4/27 15 5 15 1.000
Pulmonary disease (any) 5 18 15 45 .030
Asthma 4 14 9 27 .347
Chronic obstructive pulmonary disease 1 4 5 15 .205
Obstructive sleep apnoea 1 4 5 15 .205
Other 0 0 2 6 N/A
Rheumatic disease 0 0 3 9 .243
Stroke 0 0 2 6 .495
No comorbidities 9 32 5 15 .138
McCabe score
1 26 93 26 79 .269
2 or 3 2 7 7 21
Smoking
Never 18 64 15 45 .011
Ex-smoker 9 32 8 24
Current smoker 1 4 10 30
Hospital admissions in the last 12 months
Yes 0 0 9 27 .003
Influenza vaccination in 2019/2020
Yes 12/26 46 16 48 1.000
BMI: body mass index.
McCabe score, 1: non-fatal, 2: fatal in 1–4 years and 3: fatal within a year. Data are presented as no. and % or as medians with interquartile
ranges (IQR). If data are missing, the proportion of patients with the information available is marked as the denominator.
Values below .05 are shown bolded as that is the standard limit for statistical significance.
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analysis. The predictors associated with a longer dur-
ation of hospitalization were COVID-19 (hazard ratio [HR]
0.221, 95% CI 0.118, 0.416, p<.001), age (HR 0.972, CI
0.955, 0.990, p¼.002), BMI (HR 0.950, CI 0.916, 0.986,
p¼.006) and diabetes (HR 0.539, CI 0.272, 1.066, p¼.076).
At 3 months from admission, two (7%) COVID-19 and six
(18%) influenza patients had been readmitted to the
hospital at least once (p¼.269). During the three months
following admission, one terminally ill influenza patient
died whereas no additional COVID-19 patients died.
Discussion
Our study is one of the first prospective studies compar-
ing the clinical characteristics and outcomes of hospital-
ized adult patients with COVID-19 or seasonal influenza
Table 2. Characteristics and laboratory and radiological findings of COVID-19 and influenza patients.
COVID-19 Influenza
Characteristics and findings No. % No. % p Value
Total 28 100 33 100
Days from symptom onset to hospitalization
Duration of symptoms at hospitalization, median days (IQR) (range) 10 (7–12) [1–23] N/A 3 (2–5) [1–8] N/A <.001
0–3 days 4 14 25 76
4–7 days 6 21 8 24
8 days 18 64 N/A N/A
Reported SARI symptoms
Fever 38 28 100 33 100 N/A
Headache 22/25 88 16/31 52 .004
Myalgia 15/25 60 15/31 48 .430
Deterioration of general condition 27 96 32 97 1.000
Cough 27 96 30 91 .618
Sore throat 8/24 33 17/32 53 .179
Dyspnoea 26 93 29 88 .678
Sudden onset 11/23 48 19/31 61 .410
Clinical characteristics at admission, median (IQR)
Temperature 38.4 (37.5–38.9) N/A 38.4 (37.6–39.4) N/A .482
Fever 38 17 61 22 67 .790
Respiratory rate 22 (18–28) N/A 20 (18–24) N/A .401
Oxygen saturation on room air 93 (90–94) N/A 94 (90–96) N/A .616
NEWS2 score (IQR) [range] 5 (3–6)[0–8] N/A 4 (2–6)[0–10] N/A .423
Laboratory results at admission, median (IQR)
Haemoglobin, g/L (ref. range 134–167 men, 117–155 women) 142 (129–149) N/A 134 (123–145) N/A .078
Anaemia 4 14 10 30 .222
Leukocyte count, 109/L (reference range 3.4–8.2) 5.1 (4.0–6.3) N/A 6.7 (5.4–10.9) N/A .002
Leukopenia 3/27 11 1 3 .318
Leukocytosis 3/27 11 13 39 .019
Platelet count, 109/L (150–360) 201 (129–269) N/A 182 (164–218) N/A .538
Thrombocytopenia <150 109/L 11 39 4 12 .019
C-reactive protein, mg/L (<4) (IQR) [range] 55 (39–119) [12–186] N/A 57 (28–117) [7–214] N/A .965
Creatinine, lmol/L (60–100 men, 50–90 women) (IQR) [range] 75 (57–87) [42–740] N/A 77 (66–88) [40–557] N/A .406
Alanine aminotransferase, U/L (<50 men, <30 women) (IQR) [range] 42 (30–75) [19–127] N/A 23 (18–47) [12–123] N/A .011
Laboratory findings during hospitalization, median (IQR)
Anaemia 7 25 11 33 .578
Leukopenia 6 21 4 12 .490
Lymphopenia 18/25 72 11/19 58 .357
Thrombocytopenia < 150 109/L 11 39 9 27 .414
Highest C-reactive protein, mg/L [range] 159 (90–239) [12–410] N/A 79 (42–171) [8–289] N/A .019
Highest creatinine, lmol/L [range] 76 (60–89) [45–740] N/A 80 (66–91) [47–731] N/A .482
Highest alanine aminotransferase, U/L [range] 66 (42–190) [19–457] N/A 23 (18–52) [12–140] N/A <.001
Radiological findings in chest X-ray at admission
No findings 5 18 12 36 .154
Linear opacities 4 14 14 42 .024
Bilateral basal 3 11 14 42
Bilateral peripheral 1 4 0 0
Ground glass opacities/consolidation 19 68 7 21 <.001
Unilateral or local 0 0 2 6
Bilateral basal 8 29 4 12
Bilateral perihilar 0 0 1 3
Bilateral peripheral 9 32 0 0
Bilateral diffuse 2 7 0 0
SARI: severe acute respiratory infection.
Data are presented no. and % or as medians with interquartile ranges (IQR). If data are missing, the proportion of patients with the information available is marked
as the denominator when applicable. Of the SARI symptoms, none of the patients reported malaise and all had fever, thus malaise and feverishness were left out
of the table. Leukocyte count was missing from one COVID-19 patient at admission. ALAT was taken only from 25/28 of COVID-19 and 19/33 of influenza patients.
Values below .05 are shown bolded as that is the standard limit for statistical significance.
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with clinical pictures ranging from mild disease to ARDS.
We observed that pulmonary diseases, smoking and pre-
vious hospital admissions were less common among
COVID-19 than influenza patients. At admission, their
symptoms, disease severity and laboratory findings were
similar but chest X-ray findings differed. COVID-19
patients developed a more serious disease and required
longer hospitalization.
COVID-19 patients had no previous hospitalizations
during the past 12 months, 32% had no comorbidities
compared with 15% of influenza patients and their
comorbidities were less serious based on their McCabe
score; however, the latter two findings did not reach
statistical significance. Together these findings imply
that COVID-19 patients were previously healthier than
influenza patients. This is consistent with a recent study
by Zayet et al., where they compared adult outpatients
and inpatients with COVID-19 or influenza in a French
hospital and found that 48.6% of COVID-19 and 23.4%
of influenza patients had no comorbidities and the
Charlson comorbidity index of COVID-19 patients was
lower; however, the numbers are not entirely compar-
able as their study included outpatients [28].
The lower prevalence of pulmonary diseases among
COVID-19 patients was not limited to smoking-related
COPD but was also seen for asthma and obstructive
sleep apnoea, which were all more prevalent among
influenza patients (Table 1). Whether this relates to influ-
enza viruses affecting bronchi more than SARS-CoV-2 for
example due to different viral receptors (ACE2 for SARS-
CoV-2 and sialic acid-containing molecules for influenza)
and viral tropism, remains a subject for further investiga-
tion [1,12,29].
Influenza patients were hospitalized earlier after
symptom onset than patients with COVID-19 as in previ-
ous publications [28,30]. Fever, cough and dyspnoea
were the most common symptoms in both groups.
Headache was significantly more common among
COVID-19 than influenza patients as also previously
reported [28]. Differences in laboratory findings at
admission were not remarkable enough to enable differ-
ential diagnostics based on laboratory findings alone. As
Figure 2. Chest X-rays of COVID-19 and influenza patients at admission. (A) An 88-year-old man, influenza, day 6 of symptoms: bilateral
basal linear opacities. (B) A 28-year-old man with COVID-19, day 9 of symptoms, bilateral basal ground-glass opacities (GGOs). (C) A 51-
year-old woman with COVID-19, day 13 of symptoms: bilateral peripheral GGO and consolidations. (D) A 68-year-old man with COVID-19,
the third day of symptoms: bilateral diffuse GGO and consolidations.
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in previous studies, laboratory findings associated with
COVID-19 included lymphocytopenia, thrombocytopenia
and elevated liver enzymes [9,10,18,24]. During hospital-
ization, CRP values rose significantly higher among
COVID-19 patients especially in patients admitted to ICU,
which is consistent with previous finding of elevated
CRP being a risk factor for COVID-19 disease progres-
sion [25].
Of the COVID-19 patients, 18% had no radiological
abnormalities in chest X-ray at admission compared with
41% in a previous study, which is likely explained by the
bigger proportion of severe disease in our study [10]. In
line with previous CT findings, bilateral basal or periph-
eral GGOs and consolidations were typically seen in the
chest X-rays of COVID-19 patients, which may help in
differential diagnostics. In chest CTs of COVID-19
Table 3. Outcomes of COVID-19 and influenza patients.<.001 .03
COVID-19 Influenza
Outcomes N % N % p Value
Total 28 100 33 100
Severity of disease
Mild illness 1 4 1 3 .906
Pneumonia 1 4 13 39 <.001
Severe pneumonia 18 64 18 55 .441
ARDS 8 29 1 3 .005
Outcomes during hospitalization
Duration of hospitalization at HUS, median (IQR) [range] 6 (4–21) [1–64] N/A 3 (2–4) [1–24] N/A <.001
Admission to close observation 2 7 3 9 1.000
Admission to ICU 8 29 2 6 .034
Median stay at ICU (range) 20 (11–41) N/A 9.5 (3–16) N/A .267
Supplemental oxygen required 26 93 19 58 .003
Invasive ventilation 8 29 1 3 .009
Death 1 4 0 0 .459
Outcome at 30 days from admission
Discharged 24 86 31 94 .282
Hospitalized at HUS 3 11 0 0 .054
Hospitalized at rehabilitation hospital 0 0 2 6 .185
Dead 1 4 0 0 .274
Readmission to HUS within 30 days from admission 0 0 2 6 .495
Outcome at 3 months from admission
Readmitted to HUS within 3 months from admission 2 7 6 18 .269
Dead 1 4 1 3 1.000
ARDS: acute respiratory distress syndrome; ICU: intensive care unit; HUS: Helsinki University Hospital.
Data are presented no. and % or as medians with interquartile ranges (IQR). If data is missing, the proportion of patients with the information available is marked
as the denominator.
Values below .05 are shown bolded as that is the standard limit for statistical significance.
Figure 3. Kaplan–Meier curves for the duration of hospitalization among COVID-19 and influenza patients.
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patients, initially unilateral and multifocal GGO evolving
to diffuse bilateral GGO and later consolidations in the
course of the infection have been described [31].
Rounded opacities, interlobular septal thickening and
peripheral distribution and GGO in the CTs of ARDS
patients have been more common among COVID-19
than influenza patients [32,33].
Despite similar clinical presentation at admission,
COVID-19 patients developed a more severe disease dur-
ing hospitalization and required longer hospitalization
than influenza patients. In multivariable Cox regression
analysis, also increasing age, higher BMI and diabetes
were associated with longer hospitalization. In previous
studies, along with age and other comorbidities, obesity
has been a risk factor for severe disease and ICU admis-
sion in both COVID-19 and influenza, which supports
our findings [34,35]. In the comparison between COVID-
19 and influenza by Zayet et al., no difference in the
duration of hospitalization or ICU admissions was found,
however in a larger preprint study by Donnino et al.
hospitalized COVID-19 patients were hospitalized longer
and more likely to require mechanical ventilation or die
than hospitalized influenza patients, which is in line with
our observations [28,36].
Of the COVID-19 patients included in our study, 29%
were admitted to the ICU and 4% died compared with
6% and 0% of influenza patients. In a recent large
study from the USA, 14.2% of hospitalized COVID-19
patients were admitted to ICU and 21% died [37].
These differences may be explained by the exclusion of
institutionalized and elderly patients with poor progno-
sis from our study and by other differences in patient
populations and treatment strategies. Our findings are
aligned with the figures from the whole HUS Helsinki
University Hospital, where 629 COVID-19 patients had
been hospitalized by 11 June 2020, 139 (22%) of them
had been admitted to ICU and 38 (6%) had died (per-
sonal communication).
In a previous study, COVID-19 patients with ARDS
were older, had lower severity of illness scores at pres-
entation and lower Sequential Organ Failure Assessment
(SOFA) score-adjusted mortality than H1N1 patients with
ARDS [33]. In our study, there were too few ARDS
patients for similar comparisons but ARDS developed
more often among COVID-19 patients (29% vs. 3%). This
is consistent with the study by Donnino et al., who
found that hospitalized COVID-19 patients required
mechanical ventilation significantly more often than hos-
pitalized influenza patients and in 94% of COVID-19
cases the reason was ARDS [36].
Our study setting offered several advantages. We
included COVID-19 patients since the beginning of the
outbreak in Finland. All SARI-patients were systematically
interviewed and recruited usually before their COVID-19
or influenza test results were available, minimizing selec-
tion bias. Data were verified from several sources.
Patients had known outcomes as the follow-up lasted
until the last patient was discharged. The community-
dwelling working-age population of Espoo, the second
largest city of Finland, is well represented as Jorvi
Hospital provides their specialized care. All patients were
recruited during the same influenza season and 88%
had influenza A (H1N1) pdm09, the offspring of the pan-
demic A (H1N1) of 2009 currently circulating as seasonal
influenza. Thus, the variation in the clinical course of
influenza due to different circulating influenza strains or
different composition of seasonal influenza vaccination
was minimized.
Our study had several limitations. The sample size
was small, which should be taken into account when
interpreting the results. All patients admitted to Jorvi
Hospital with COVID-19 or influenza were not eligible;
for example, they lived outside of the Jorvi Hospital
catchment area or did not consent to participate. Elderly
patients were underrepresented as patients with pre-
existing treatment limitations or not requiring special-
ized care were admitted to the secondary care Espoo
Hospital. The time from symptom onset to hospitaliza-
tion may not be completely comparable between
COVID-19 and influenza patients because, until March,
only patients with symptom onset within the last
seven days were included. Furthermore, this study is
based on clinical data and no extra laboratory testing or
radiological imaging was done in addition to the detec-
tion of influenza and SARS-CoV-2 RNA. Consequently, CT
scans, coagulation markers, cardiac biomarkers or blood
gas analyses were mostly not available and thus were
not included here. During the COVID-19 epidemic, occa-
sionally SARS-CoV-2 detection alone was conducted
without influenza testing on clinical grounds, however,
of the COVID-19 patients included in this study, 21
(75%) were tested for influenza and no co-infections
were found.
In conclusion, COVID-19 requiring hospitalization had
a more severe clinical course than influenza. As SARS-
CoV-2 and influenza may continue to circulate simultan-
eously and influenza already strains health care capacity
every influenza season, this has important implications
for public health policies for COVID-19 mitigation. Larger
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studies are needed to further examine the differences
between COVID-19 and influenza.
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